{"id":"W2971577153","doi":"10.1016/s1474-4422(19)30239-x","title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; McGill University; University of Toronto; NeuroRx Research (Canada)","funders":"Schweizerische Multiple Sklerose Gesellschaft; Bayer Schering; Javna Agencija za Raziskovalno Dejavnost RS; Ministerstvo Školství, Mládeže a Tělovýchovy; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Sanofi; European Commission; Bayer; Celgene; Biogen; AbbVie; MedImmune; Merck; Teva Pharmaceutical Industries; Novartis; Roche","keywords":"Medicine; Internal medicine; Population; Clinical endpoint; Placebo; Clinical trial; Physical therapy; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001034052,0.0002702546,0.001317483,0.0001734627,0.00008484624,0.00001521611,0.0002834646,0.0001554486,0.00009528516],"category_scores_gemma":[0.001965727,0.000188369,0.0001604605,0.0001941374,0.0003793526,0.00007480403,0.0003183181,0.0007032263,0.00002600589],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004409683,"about_ca_system_score_gemma":0.00005055764,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000185847,"about_ca_topic_score_gemma":0.0003003591,"domain_scores_codex":[0.9971166,0.0006810937,0.0006842783,0.0005230238,0.0003332024,0.000661752],"domain_scores_gemma":[0.9941926,0.004680793,0.0002314622,0.000702358,0.00007213958,0.0001206265],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9461797,0.0006841781,0.00641512,0.00009012594,0.0002000519,0.00001547865,0.001209104,0.0000569863,0.03295802,0.00001462946,0.0003052209,0.01187131],"study_design_scores_gemma":[0.9289317,0.008408654,0.05168127,0.0001448081,0.0001447522,0.000007176805,0.0001453609,0.007110882,0.001092048,0.000004453107,0.00216218,0.0001667745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901035,0.000688473,0.00001517851,0.004148701,0.0007112901,0.003239709,0.00003181746,0.00004422255,0.00101704],"genre_scores_gemma":[0.9968216,0.00213888,0.0001160025,0.0004022808,0.0003369877,0.00006241356,0.00001561466,0.00003543948,0.00007080237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04526615,"threshold_uncertainty_score":0.7681466,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0951953261825901,"score_gpt":0.3336784796590158,"score_spread":0.2384831534764257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}